The Asia-Pacific diabetes care devices market is expected to register a CAGR of about 7.8% during 2018-2023 (the forecast period). China is anticipated to dominate the market during the forecast period, due to the presence of huge diabetic patient pool in the region.

Presence of Large Diabetic Population

Asia-Pacific is the fastest growing region in the global market, due to the presence of a huge diabetic population. China and India contribute to major shares in the Asia-Pacific diabetes care devices market, due to the presence of heavy diabetic population. According to WHO, over 60% of the diabetic people in the world are living in Asia-Pacific, where India and China are the major contributing countries, with a diabetic population of 90 million and 62 million, respectively. By 2030, both of the countries together are expected to witness about a diabetic population of half a billion individuals. Therefore, growing diabetic and obese population across Asia-Pacific is driving the market growth. Additionally, innovative product development and growing awareness, regarding diabetic care, are the factors that are further driving the market for diabetes care devices in Asia-Pacific.

Lack of Proper Reimbursement Policies

In India, approximately 10% of the population avails health insurance coverage and over 80% of the healthcare costs are out-of-pocket expenses.

Device manufacturers should be aware of the coverage limits and demographics while pricing their products, in order to capture the largest possible market share. For mature medical products, such as heart valves, stents etc., the coverage has been determined and the data is available for insurers. However, to develop new products, like glucose meters and diabetes devices, the coverage has not been established. Therefore, these products are available only to a limited people. Thus, a lack of reimbursement policies and high cost associated with diabetes care devices, in developing countries of Asia-Pacific, are likely to impede the market growth.

China to Dominate the Market

China is dominating the Asia-Pacific diabetes care devices market. The growth of the Chinese market can be attributed to the factors like rapid urbanization, high calorie diet, and physical inactivity, which are the major reasons for the high prevalence of diabetes in China. India is anticipated to grow tremendously during the forecast period. The growing prevalence of diabetes, rising awareness about diseases, changing food habits, and a rise in disposable incomes in the country are likely to augment the growth of the Indian diabetes care devices market.

Key Developments in the Market

January 2018 - Eli Lilly and Company and Livongo Health, a leading consumer digital health company, entered a strategic collaboration to study the real-world evidence and develop new insights, in oder to reduce the burden on people living with diabetes.
June 2017 – Roche acquired mySugr to form a leading open platform for digital diabetes management.

Major Players: Abbott Laboratories, Acon Laboratories, Inc., Bayer AG, Becton, Dickinson and Company, Eli Lilly & Co., F. Hoffmann-La Roche Ltd, Johnson and Johnson, Medtronic Plc, Novo Nordisk A/S, and Sanofi, among others.

Reasons to Purchase this Report

Current and future Asia-Pacific diabetes care devices market outlook in the developed and emerging markets
Various perspectives of the market with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest rates growth during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

1. Introduction

1.1 Scope of Study

1.2 Market Definition

1.3 Executive Summary

2. Research Methodology

2.1 Study Deliverables

2.2 Study Assumptions

2.3 Research Phases

3. Market Insights

3.1 Technology Trends

3.2 Industry Attractiveness - Porter's Five Forces Analysis

3.2.1 Bargaining Power of the Suppliers

3.2.2 Bargaining Power of the Consumers

3.2.3 Threat of New Entrants

3.2.4 Threat of Substitute Products and Services

3.2.5 Competitive Rivalry within the Industry

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

5. Market Segmentation and Analysis

5.1 Monitoring Device

5.1.1 Self Blood Glucose Monitoring

5.1.1.1 Blood Glucose Meters

5.1.1.1.1 Blood Glucose Meters, Revenue(2012-2023)

5.1.1.1.2 Blood Glucose Meters, Volume(2012-2023)

5.1.1.2 Blood Glucose Test strips

5.1.1.2.1 Blood Glucose Test strips, Revenue(2012-2023)

5.1.1.2.2 Blood Glucose Test strips, Volume(2012-2023)

5.1.1.3 Lancets

5.1.1.3.1 Lancets, Revenue(2012-2023)

5.1.1.3.2 Lancets, Volume(2012-2023)

5.1.2 Continous Blood Glucose Monitoring

5.1.2.1 Durables

5.1.2.1.1 Durables, Revenue(2012-2023)

5.1.2.1.2 Durables, Volume(2012-2023)

5.1.2.2 Sensors

5.1.2.2.1 Sensors, Revenue(2012-2023)

5.1.2.2.2 Sensors, Volume(2012-2023)

5.2 Management Device

5.2.1 Insulin Pump

5.2.1.1 Insulin Pump Device

5.2.1.1.1 Insulin Pump Devices, Revenue(2012-2023)

5.2.1.1.2 Insulin Pump Devices, Volume(2012-2023)

5.2.1.2 Insulin Pump Reservoir

5.2.1.2.1 Insulin Pump Reservoirs, Revenue(2012-2023)

5.2.1.2.2 Insulin Pump Reservoirs, Volume(2012-2023)

5.2.1.3 Infusion Set

5.2.1.3.1 Infusion Sets, Revenue(2012-2023)

5.2.1.3.2 Infusion Sets, Volume(2012-2023)

5.2.2 Syringes

5.2.2.1 Syringes, Revenue(2012-2023)

5.2.2.2 Syringes, Volume(2012-2023)

5.2.3 Cartridges

5.2.3.1 Cartridges, Revenue(2012-2023)

5.2.3.2 Cartridges, Volume(2012-2023)

5.2.4 Disposable Pens

5.2.4.1 Disposable Pens, Revenue(2012-2023)

5.2.4.2 Disposable Pens, Volume(2012-2023)

5.2.5 Jet Injectors

5.2.5.1 Jet Injectors , Revenue(2012-2023)

5.2.5.2 Jet Injectors , Volume(2012-2023)

5.2.6 Geographical Analysis

5.2.6.1 Australia

5.2.6.2 Australia, Revenue (2012-2023)

5.2.7 Australia, Volume (2012-2023)

5.2.7.1 India

5.2.7.2 India, Revenue (2012-2023)

5.2.8 India, Volume (2012-2023)

5.2.8.1 Indonesia

5.2.8.2 Indonesia, Revenue (2012-2023)

5.2.9 Indonesia, Volume (2012-2023)

5.2.9.1 Thailand

5.2.9.2 Thailand, Revenue (2012-2023)

5.2.10 Thailand, Volume (2012-2023)

5.2.10.1 Philippines

5.2.10.2 Philippines, Revenue (2012-2023)

5.2.11 Philippines, Volume (2012-2023)

5.2.11.1 Vietnam

5.2.11.2 Vietnam, Revenue (2012-2023)

5.2.12 Vietnam, Volume (2012-2023)

5.2.12.1 China

5.2.12.2 China, Revenue (2012-2023)

5.2.13 China, Volume (2012-2023)

5.2.13.1 South Korea

5.2.13.2 South Korea, Revenue (2012-2023)

5.2.14 South Korea, Volume (2012-2023)

5.2.14.1 Japan

5.2.14.2 Japan, Revenue (2012-2023)

5.2.15 Japan, Volume (2012-2023)

5.2.15.1 Malaysia

5.2.15.2 Malaysia, Revenue (2012-2023)

5.2.16 Malaysia, Volume (2012-2023)

5.2.16.1 Rest of Asia Pacific

5.2.16.2 Rest of Asia Pacific, Revenue (2012-2023)

6. Rest of Asia Pacific, Volume (2012-2023)

7. Key Player Profiles

7.1 Abbott Diabetes Care

7.2 Roche

7.3 Johnson & Johnson

7.4 Arkray

7.5 Ascensia Diabetes Care

7.6 AgaMatrix, Inc.

7.7 LifeScan

7.8 Sanofi

7.9 Dexcom

7.10 Medtronic

7.11 Novo Nordisk

7.12 Becton Dickinson

7.13 Eli Lilly

7.14 Ypsomed Holding AG

* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.

Asia-Pacific Diabetes Care Devices Market - Segmented by Product and Geography - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Looking to buy the report?